hylenex logo Baxter wordmark
This site is Intended for US Healthcare Professionals
Site Map  |  Contact Us  |  Request More Information  |  Buying Information
Send Sub-Q to the rescue

Resources

BIBILIOGRAPHY

The bibliography is provided to direct you to further published information regarding hyaluronidase and related topics. The bibliography is a selection but not a comprehensive list of the available published literature.

hylenex recombinant (hyaluronidase human injection)

Bookbinder LH, Hofer A, Haller MF, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics.
J Control Release. 2006;114:230-241.

Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration.
Expert Opin Drug Deliv. 2007;4:427-440.

Haller MF. Converting intravenous dosing to subcutaneous dosing with recombinant humanhyaluronidase.
Pharm Tech. 2007;10:861-864.

Pirrello RD, Ting Chen C, Thomas SH. Initial experiences with subcutaneous recombinant human hyaluronidase.
J Palliat Med. 2007;10:861-864.

Thomas JR, Yocum RC, Haller MF, von Gunten CF. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study. J Palliat Med. 2007;10:1312-1320.

Yocum RC, Kennard D, Heiner LS. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial.
J Infus Nurs. 2007;30:293-299.

Hyaluronidase

Dudzinski DM, Kesselheim AS. Scientific and legal viability of follow-on protein drugs.
N Engl J Med. 2008;358:843-849.

Ebo DG, Goossens S, Opsomer F, Bridts CH, Stevens WJ. Flow-assisted diagnosis of anaphylaxis to hyaluronidase.
Allergy. 2005;60:1333-1334.

Jaworski A, Farley JE Jr. Hyaluronidase in administration of fluids.
Am J Dis Child. 1950;79:59-64.

Schwartzman J. Hyaluronidase: a review of its therapeutic use in pediatrics.
J Pediatr. 1951;39:491-502.

Subcutaneous Hydration

Frisoli A Jr, de Paula AP, Feldman D, and Nasri F. Subcutaneous hydration by hypodermoclysis. A practical and low cost treatment for elderly patients. Drugs Aging. 2000;16:313-319.

Lipschitz S, Campbell AJ, Roberts MS, Wanwimolruk S, McQueen EG, Firth LA. Subcutaneous fluid administration in elderly subjects: Validation of an under-used technique. Am J Geriatr Soc. 1991;29:6-9.

Lybarger EH. Hypodermoclysis in the home and long-term care settings. J Infus Nurs. 2009;32:40-44.

Remington R and Hultman T. Hypodermoclysis to treat dehydration: a review of the evidence.
J Am Geriatr Soc. 2007;55(12):2051-2055.

Steiner MJ, DeWalt DA, Byerley JS. Is this child dehydrated? JAMA. 2004;291:2746-2754.

Thomas DR, Cote TR, Lawhorne L, et al and Dehydration Council. Understanding clinical dehydration and its treatment. J Am Med Dir Assoc. 2008;9:292-301.

Walsh G. Hypodermoclysis: an alternate method for rehydration in long-term care.
J Infus Nurs. 2005;28:123-129.

Pediatric IV Considerations

Spandorfer PR, Alessandrini EA, Joffe MD, Localio R, Shaw KN. Oral versus intravenous rehydration of moderately dehydrated children: a randomized, controlled trial.
Pediatrics. 2005;115:295-301.

Wathen JE, MacKenzie T, Bothner JP. Usefulness of the serum electrolyte panel in the management of pediatric dehydration treated with intravenously administered fluids.
Pediatrics. 2004;114:1227-1234.

Zempsky WT. Pharmacologic approaches for reducing venous access pain in children.
Pediatrics. 2008;122:S140-S153.

Absorption and Dispersion of Other Injected Drugs

Alwitry A, Chaudhary S, Gopee K, Butler TK, Holden R. Effect of hyaluronidase on ocular motility in sub-Tenon’s anesthesia: randomized controlled trial. J Cataract Refract Surg. 2002;28:1420-1423.

Dempsey GA, Barrett PJ, Kirby IJ. Hyaluronidase and peribulbar block. Br J Anaesth. 1997;78:671-674.

Eberhart AH, Weiler CR, Erie JC. Angioedema related to the use of hyaluronidase in cataract surgery.
Am J Ophthalmol. 2004;138:142-143.

Guise P, Laurent S. Sub-Tenon’s block: the effect of hyaluronidase on speed of onset and block quality.
Anaesth Intensive Care. 1999;27:179-181.

Kallio H, Paloheimo M, Maunuksela EL. Hyaluronidase as an adjuvant in bupivacaine-lidocaine mixture for retrobulbar/peribulbar block. Anesth Analg. 2000;91:934-937.

Mantovani C, Bryant AE, Nicholson G. Efficacy of varying concentrations of hyaluronidase in peribulbar anesthesia.
Br J Anaesth. 2001;86:876-878.

Rowley SA, Hale JE, Finlay RD. Sub-Tenon’s local anaesthesia: the effect of hyaluronidase.
Br J Ophthalmol. 2000;84:435-436.

Reimbursement

Thompson CA. Medicare updates outpatient payment system. Am J Health Syst Pharm. 2007;64:2526-2528.

Important Risk Information for Healthcare Professionals
Indications

HYLENEX recombinant (hyaluronidase human injection) is indicated as an adjuvant to increase the absorption and dispersion of other injected drugs; for subcutaneous fluid administration; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents.

Important Risk Information
  • Hypersensitivity to hyaluronidase or any other ingredient in the formulation is a contraindication to the use of this product.
  • Discontinue HYLENEX recombinant (hyaluronidase human injection) if sensitization occurs.
  • Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs.
  • Hyaluronidase should not be injected into or around an infected or acutely inflamed area because of the danger of spreading a localized infection.
  • Hyaluronidase should not be used to reduce the swelling of bites or stings.
  • Hyaluronidase should not be applied directly to the cornea.
  • Hyaluronidase should not be used for intravenous injections because the enzyme is rapidly inactivated.
  • Furosemide, the benzodiazepines and phenytoin have been found to be incompatible with hyaluronidase.
  • The most frequently reported adverse experiences have been mild local injection site reactions, such as erythema and pain.
  • Hyaluronidase has been reported to enhance the adverse events associated with co-administered drug products.
  • Allergic reactions (urticaria or angioedema) have been reported in less than 0.1% of patients receiving hyaluronidase.
  • Anaphylactic-like reactions following retrobulbar block or intravenous injections have occurred, rarely.
  • When hyaluronidase is added to a local anesthetic agent, it hastens the onset of analgesia and tends to reduce the swelling caused by local infiltration, but the wider spread of the local anesthetic solution increases its absorption; this shortens its duration of action and tends to increase the incidence of systemic reaction.
  • Edema has been reported most frequently in association with subcutaneous fluid administration.
  • The rate and volume of subcutaneous fluid administration should not exceed those employed for intravenous infusion. As with all parenteral fluid therapy, use the same precautions for restoring fluid and electrolyte balance.
  • During subcutaneous fluid administration, special care must be taken in pediatric patients to avoid over hydration by controlling the rate and total volume of the infusion.
  • When solutions devoid of inorganic electrolytes are given subcutaneously, hypovolemia may occur.